Výsledky vyhledávání - "Dimitry Nosov"

Publikováno v: European urology. 82(4)

In the phase 3 KEYNOTE-426 (NCT02853331) trial, pembrolizumab + axitinib demonstrated improvement in overall survival, progression-free survival, and objective response rate over sunitinib monotherapy for advanced renal cell carcinoma (RCC).To evalua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9723e0ee94f90feee8cda326ca0ef342
https://pubmed.ncbi.nlm.nih.gov/36175267

Zobrazit plný text záznamu

Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC)

Publikováno v: Journal of Clinical Oncology. 34:499-499

499 Background: Cabozantinib (C) inhibits tyrosine kinases including VEGFRs, MET, and AXL. The METEOR phase 3 trial (NCT01865747) met its primary endpoint of significant improvement in PFS with C versus everolimus (E) in pts with advanced clear cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45483d335010e4f166e537501c7209b9
https://doi.org/10.1200/jco.2016.34.2_suppl.499

Zobrazit plný text záznamu

Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902)

Autor: Thomas E. Hutson, Michael N. Needle, Piotr Tomczak, Oleg Lipatov, Tim Eisen, Cora N. Sternberg, Igor Bondarenko, Dimitry Nosov

Publikováno v: Journal of Clinical Oncology. 33:4557-4557

4557 Background: An extension and open access study allowed follow up of patients (pts) from TIVO-1 (301), an open label, phase III multinational trial in which pts with metastatic renal cell carci...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ab19e7aafb308670e193a44fbfd1ed70
https://doi.org/10.1200/jco.2015.33.15_suppl.4557

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání